Printer Friendly

ProteoTech, Tasly sign Alzheimer's drug development deal.

M2 PHARMA-October 4, 2010-ProteoTech, Tasly sign Alzheimer's drug development deal(C)2010 M2 COMMUNICATIONS

4 October 2010 - Chinese Tasly Pharmaceutical Co Ltd (SHA: 600535) and US ProteoTech Inc said today they have inked an agreement to co-develop ProteoTech's small molecule therapeutic, Exebryl-1, for the treatment of mild-to-moderate Alzheimer's disease.

Exebryl-1 has been shown to inhibit beta-amyloid protein aggregate formation in brain, as well as disaggregate amyloid plaques that are already present. The drug has also shown specificity against tau protein aggregates and may be the first therapeutic targeting beta-amyloid and tau protein associated with this disease.

The collaboration will focus on moving the clinical development of this drug though the regulatory process in China and the US.

Terms of the contract were not disclosed but will include an upfront payment, development costs and research funding to ProteoTech according to Manuel Menendez, managing partner of Nobel Pacific, who acted as an advisor to both companies.

Tasly will gain rights for Exebryl-1 for China and ProteoTech will retain rights for the US and the rest of the world.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2010 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2010 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Oct 4, 2010
Words:187
Previous Article:Genzyme board urges shareholders to take no action on sanofi's offer.
Next Article:VentiRx's VTX-2337 completes Phase I study in oncology.
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters